Large hereditary panels (cancer, cardiac, neurology, rare disease) plus exome, with ACMG-classified results a physician can act on and genetic counselling available.

Hereditary cancer, cardiac (e.g. CardioNext), neurology and carrier testing, plus ExomeReveal clinical exome with RNA reflex in ~5% of cases and ongoing “Patient for Life” reanalysis. Genetic counselling by phone/video included.

Targeted panels, not WGS/WES for consumers: Hereditary Cancer (30 genes), BRCA1/2-only, Hereditary Heart Health (30 genes), Familial Hypercholesterolemia (3 genes), plus a pharmacogenomics panel reported at ~$299. Complimentary board-certified genetic counselling included.

*Turnaround is an open question in the research — confirm at ordering. Sponsored no-cost programmes exist for people at increased risk of ovarian/gynaecologic cancer (via Ovarian Cancer Research Alliance and pharma funders) — worth asking a clinician about. Color states it does not “sell” or “share” personal information as defined by California privacy law.

A very large clinical menu: custom and disease panels, PGxome® whole exome and PGnome® whole genome (nuclear + mitochondrial DNA, with secondary findings for preventable cancer/heart/anaesthesia conditions). A strong choice for a deep, diagnostic-grade workup. One free reanalysis within 3 years on physician request.

*Open questions in the research: self-pay price and turnaround are not published; an exome-wide CNV add-on was listed at $250 on requisition forms. Do not compare directly with $199–$499 DTC prices. Ownership note: a subsidiary of Exact Sciences; Abbott completed its ~$21bn acquisition of Exact Sciences in March 2026. No change to test availability was reported.

Targeted panels, WES and WGS with a rare-disease and hereditary-cancer focus; described in sources as the largest US clinical exome/genome volume. Genetic counselling support included.

*Sources give billed/reimbursement figures, not a checkout price: exome ~$1,500–$4,000 billed, average reimbursement ~$3,750 in Q4 2025. Your quote depends on indication and insurance. Privacy note: GeneDx earned ~$42m in 2025 from data licensing / biopharma partnerships using de-identified data — ask about research consent / opt-out if that matters to you.

The prescriber-relevant special case: a cheek-swab PGx panel focused on ~60 psychiatric medicines (genes including CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP2B6), reported as a green / yellow / red chart for the prescriber.

Evidence caveat: strongest for guiding antidepressant selection in some populations; weaker/mixed for other claims. It does not replace clinical judgement, interaction checks, or drug monitoring. Other clinician-ordered PGx options in the research: Tempus nP (~$295 self-pay, 13 genes), OneOme RightMed (~$349, 27 genes, 100+ drugs), Genomind (~$599).

30× WGS through a CLIA-certified, CAP-accredited US lab, with polygenic risk scores, family-planning tools, and a genetic-counselling option.

*That discrepancy is itself a reason to ask what the current panel covers. One review notes its polygenic scores have not been published/validated in peer-reviewed journals, and reports give risk information rather than tailored diet/supplement prescriptions. Samples were reported destroyed within 60 days in one roundup — verify in the current policy.

30× WGS of all ~30,000 genes/chromosomes, with downloadable FASTQ/BAM/VCF files and a bundle covering a Next-Gen Disease Screen for 15,000+ conditions, carrier, autoimmune, cardiovascular, EDS and medication-response markers.

Total-cost warning: marketplace apps run ~$0–$399 each, so a comprehensive workup can cost well above $399. Reviewers stress results are not clinical/diagnostic. *Transparency gap flagged: the current partner lab and its CAP/CLIA status were not named on the product page checked.

30× WGS (claimed on Illumina NovaSeq X) with FASTQ/BAM/VCF free to download; 90+ reports included, 760–810+ with Premium. Reports are described as “physician-ready” (ACMG-classified) — but this remains a consumer product, not a clinician-ordered diagnostic.

Was a well-regarded 30× WGS service (~$299 at peak; 0.4× low-pass from ~$99) with FASTQ/BAM/VCF and weekly research reports.

That listing was not verified as an active Nebula offer, and the dedicated shutdown review says there is nothing left to buy. Treat any 2026 page still selling “Nebula” as a live kit with suspicion. Downloaded files can still be uploaded to third-party analysis tools.

The only mainstream DTC kit with a set of FDA-authorized health, carrier and pharmacogenetics reports — 150+ reports in Health + Ancestry. But it is a SNP chip (~630,000 spots, ~0.1% of the genome), not sequencing.

Ancestry, relatives and historical records are the product (tens of millions of testers, 60bn+ records). Health is limited to 75+ wellness-style traits, with no clinical health-report category comparable to 23andMe.

Privacy: states it does not sell personal information; research is opt-in. Account deletion, DNA-results deletion, sample destruction and research withdrawal are four separate controls, and data already shared with matches may persist. Acquired by Blackstone in 2020 — a structural point some privacy reviews flag.

Ancestry/ethnicity, DNA matches and family-history tools, with a ~9.6m database particularly strong for European, Middle Eastern and Scandinavian ancestry.

The reported move to low-pass 2× WGS is a real upgrade for matching — but genealogy-grade, not 30× clinical-grade. The health upgrade is not a substitute for clinical testing. Watch the total: a $32 sale kit can become a $200–$300 annual charge if a trial is not cancelled (per a 2026 review). Privacy reported as comparatively favourable: sample destruction is the default, research is opt-in, and it states it will not sell/license data without explicit consent — verify in the current policy.

A targeted nutrigenomic panel interpreted by your own practitioner and turned into a meal plan: nutrient metabolism and deficiency risk (vitamins A, B12, C, D, E, folate, choline, iron, calcium), cardiometabolic health, weight management, gluten / lactose / caffeine predispositions, and fitness (power vs endurance, injury risk, bone mass).

Important: a “gluten” or “lactose” flag is a genetic predisposition to intolerance, not a diagnosis of coeliac disease or food allergy. Ask which panel your practitioner uses — an older 45-marker panel is still cited by many clinics. Example pricing in sources: $398–$399 test alone in older listings; $530, or $720 with a dietitian plan + 60-min consultation, at one clinic. Ask the practitioner for the lab’s data-retention and deletion terms — they were not published in the sources found.

DNAfit now redirects to CircleDNA, which uses next-generation sequencing (exome-based) rather than a simple chip: diet and nutrient insights, personalised meal plans, fitness, stress/sleep — plus, in broader panels, disease-risk, carrier and pharmacogenomics reports. Includes a free 30-minute consultation (genetics-trained coach / counsellor, depending on panel).

CircleDNA pricing in sources: Vital (125+ reports) ~$189, Health (115+ reports) ~$499, Premium (500+ reports) ~$629 — it varies sharply by region and promotion, so verify the current panel and price. An older DNAfit privacy review flagged clauses allowing data to be passed to third parties for research with or without consent — read the current CircleDNA policy before ordering.

Smaller or narrower options from the research, for completeness in a dietitian conversation:

Nutrigenomics reports in general are wellness/predisposition reports, not diagnoses. Evidence is better supported for vitamin D, caffeine, lactose and some lipid/weight genes than for many “eat for your DNA” claims.